Researchers in Oxford launch Phase 1 Clinical Trial of MAP vaccine in Healthy Adult Volunteers

Researchers in Oxford are recruiting to a phase I clinical trial to determine the safety and immunogenicity of the candidate Mycobacterium avium subspecies paratuberculosis (MAP) vaccine ChAdOx2 HAV in healthy adult volunteers.

The Jenner Institute, part of the Nuffield Department of Medicine, is looking for healthy volunteers to take part in a trial testing the safety and immunogenicity of a new vaccine. If you are aged 18-50, are in good health you may be eligible to participate. Volunteers are compensated for their time and travel during the study period of 12 months. To find out more email the Volunteer Co-ordinator, on 01865-857406 or visit the Jenner Institute website

What is a Phase One Clinical Trial?

It is a trial where a small number of people, who may be healthy volunteers, are given the medicine. The vaccine or drug is being trialled in human volunteers for the first time. Researchers test for side effects and calculate what the right dose might be to use in treatment. Researchers start with small doses and only increase the dose if the volunteers don't experience any side effects, or if they only experience minor side effects.

We recommend you speak with your GP or health practitioner before taking part in a Clinical Trial and for further information go to NHS Choices.

This research is not funded or organised by Crohn's & Colitis UK, and therefore we cannot take responsibility for your involvement in the research.